SNRPA

SNRPA Full Name

small nuclear ribonucleoprotein polypeptide A

SNRPA Introduction

The SNRPA (small nuclear ribonucleoprotein polypeptide A) gene encodes one of the core protein components of the U1 small nuclear ribonucleoprotein (U1 snRNP) complex, a critical executor of pre-mRNA splicing. As a member of the RNA-binding protein family, SNRPA specifically recognizes and binds to stem-loop II of U1 snRNA, positioning it at the heart of the spliceosome machinery that removes introns from precursor messenger RNAs. Beyond its fundamental role in RNA processing, SNRPA has garnered significant clinical attention as an autoantigen in connective tissue diseases and as an emerging oncogenic driver and prognostic biomarker in multiple human cancers, including gastric cancer, hepatocellular carcinoma, lung adenocarcinoma, and breast cancer. The protein's dual function in both constitutive splicing and the regulation of alternative splicing events underlies its broad impact on cellular physiology and disease pathogenesis.

Figure 1. Strcuture of SNRPA.

Molecular Function and Spliceosome Assembly
SNRPA serves as an essential component of the U1 snRNP, one of the five major snRNPs (U1, U2, U4, U5, U6) that assemble into the spliceosome—the massive ribonucleoprotein machine responsible for intron removal from pre-mRNA. Within the U1 snRNP complex, SNRPA specifically binds to stem-loop II of U1 snRNA through its RRM domains, stabilizing the snRNA structure and contributing to the overall architecture of the particle. The U1 snRNP itself binds to the 5' splice site of precursor mRNAs through base-pairing between the 5' end of U1 snRNA and the splice site consensus sequence, and SNRPA, together with other U1-specific proteins (SNRNP70 and SNRPC), ensures the specificity and efficiency of this recognition event. The protein is required for spliceosome assembly and progression through the early stages of the splicing reaction. Beyond its role in constitutive splicing, SNRPA participates in the coupling between splicing and polyadenylation through an elegant autoregulatory mechanism. The protein inhibits the polyadenylation of its own pre-mRNA by dimerizing and binding to a specific site in the 3' untranslated region, thereby controlling its own expression levels. This self-regulatory loop ensures that SNRPA protein concentrations are maintained within appropriate limits for proper spliceosome function. The protein also plays broader roles in alternative splicing regulation, influencing the inclusion or exclusion of specific exons in target transcripts.

Conclusion
SNRPA encodes a dual-RRM RNA-binding protein that stands at the nexus of constitutive splicing, alternative splicing regulation, and disease pathogenesis. As an essential component of the U1 snRNP complex, it ensures accurate 5' splice site recognition and participates in the intricate spliceosome assembly process. Its elegant autoregulatory mechanism, wherein it inhibits polyadenylation of its own pre-mRNA through dimerization, exemplifies the sophisticated control systems governing splicing factor expression. Clinically, SNRPA spans an impressive spectrum of human diseases: it is a major autoantigen in systemic lupus erythematosus and a novel serological biomarker for systemic sclerosis, with anti-SNRPA antibodies detected in 11.25% of SSc patients. In oncology, SNRPA functions as a bonafide oncogene driving tumor progression through multiple mechanisms: promoting proliferation and EMT in gastric cancer, regulating PPDPF alternative splicing to activate PI3K-Akt signaling in hepatocellular carcinoma, controlling ERCC1 exon splicing to induce cisplatin resistance in lung adenocarcinoma, and contributing to triple-negative breast cancer aggressiveness. The convergence of these diverse roles—fundamental RNA processing, autoimmune targeting, and oncogenic transformation—positions SNRPA as a fascinating subject for continued research and a promising therapeutic target across multiple disease areas. Future studies aimed at developing SNRPA inhibitors or modulating its splicing regulatory functions may yield novel therapeutic strategies for cancer and autoimmune diseases.

Alternate Names for SNRPA

SNRPA1; small nuclear ribonucleoprotein polypeptide A; U2 small nuclear ribonucleoprotein A; Lea1; Lea1; RU2A_HUMAN; Small nuclear ribonucleoprotein polypeptide A; SNRPA1; U2 small nuclear ribonucleoprotein A; U2 small nuclear ribonucleoprotein polypeptid

• Autoimmunity Catalogue
• Autoimmunity Catalogue